What were Hikal Ltd's latest quarterly results?
Hikal Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: -134.3%
- Revenue Growth YoY: +10.4%
- Operating Margin: 16.7%
Hikal Ltd (Pharma - API & CRAMS) — fundamental analysis, earnings data, and key metrics. PE: 76.9. ROE: 7.4%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on publicly available financial data. This is educational research, not investment advice.
Hikal Ltd's latest quarterly results (Dec 2025) show
Hikal Ltd's current PE ratio is 76.9x.
Hikal Ltd's price-to-book ratio is 1.6x.
Hikal Ltd's fundamental strength based on key financial ratios
Hikal Ltd has a debt-to-equity ratio of N/A.
Hikal Ltd's return ratios over recent years
Hikal Ltd's operating cash flow is positive (FY2025).
Hikal Ltd's current dividend yield is 0.90%.
Hikal Ltd's shareholding pattern (Dec 2025)
Hikal Ltd's promoter holding has remained stable recently.
Hikal Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Based on quantitative research signals, here is why Hikal Ltd may be worth studying
Hikal Ltd investment thesis summary:
Hikal Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.